A novel chemotherapy of malignant glioma by concomitant use of inhibitors for angiogenetic factor and hypoxia-inducible factor
| Project/Area Number |
24592178
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
HAYASHI Takuro 藤田保健衛生大学, 医学部, 客員講師 (40296611)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIROSE Yuichi 藤田保健衛生大学, 医学部, 教授 (60218849)
ITO Keisuke 藤田保健衛生大学, 医学部, 助教 (70622934)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | malignant glioma / bevacizumab / rapamycin / angiogenesis / hypoxia / xenograft / 悪性グリオーマ / ベバシズマブ / ラパマイシン / 移植 / 低酸素 / 血管新生 / HIF1α / MRI / グリオーマ |
|---|
| Outline of Final Research Achievements |
Using human glioma cell line U251, biological responses of glioma cells to combination usage of angiogenesis inhibitor (bevacizumab) and chemotherapeutic agent (rapamycin) was investigated in vitro and in vivo. The result of this study suggested that the growth of glioma might be inhibited by rapamycin,which blocked the secondary angiogenesis, resulted from hypoxic state by bevacizumab. Thus, this type of concomitant therapy could be one of the novel approaches of malignant glioma.
|
Report
(4 results)
Research Products
(8 results)
